The Risk of Stroke in Patients with Acute Myocardial Infarction after Thrombolytic and Antithrombotic Treatment
New England Journal of MedicinePublished 2 July 1992
Aldo P. Maggioni, M. G. Franzosi, Eugenio Santoro, Harvey D. White, Frans Van de Werf, Gianni Tognoni
Citations283
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Patients with acute myocardial infarction who receive thrombolytic therapy have a small risk of stroke, whereas a higher body-mass index or a history of hypertension, diabetes, or smoking did not.
Abstract
Patients with acute myocardial infarction who receive thrombolytic therapy have a small risk of stroke. Treatment with t-PA as compared with streptokinase resulted in a small but significant excess of stroke. Subcutaneous heparin, given together with t-PA or streptokinase and aspirin, did not result in an increased risk of stroke.
Keywords
Medicine
The LancetTRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION
1,157 Citations1988Robert G. Wilcox, Carl Olsson +5 more
Subset analysis showed that patients who had a normal electrocardiogram (ECG) at the time of randomisation had a low case fatality rate and rt-PA was associated with a 24.5% relative reduction in 1 month fatality.
New England Journal of MedicineComparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
1,019 Citations1989The TIMI Study Group*
The ejection fraction and the incidence of death in the two groups were similar during the hospital period and total mortality within the first 6 days and at 42 days was also similar; the latter comparison was considered statistically significant according to the study criteria.
BMJSecondary prevention of vascular disease by prolonged antiplatelet treatment
1,001 Citations1988Antiplatelet Trialists' Collaboration
Antiplatelet treatment can reduce the incidence of serious vascular events by about a quarter among a wide range of patients at particular risk of occlusive vascular disease, and the balance of risk and benefit might be different for “primary” prevention among people at low absolute risk of Occlusive disease.
The LancetMEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction
911 Citations1990GRUPPOITALIANOPERLOSTUDIODELL
SK and tPA appear equally effective and safe for use in routine conditions of care, in all infarct patients who have no contraindications, with or without post-thrombolytic heparin treatment.
The LancetIn-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
620 Citations1990The International Study Group
In a study with 2 x 2 factorial design, 20,891 patients with suspected acute myocardial infarction of less than 6 h duration were randomly allocated to alteplase (recombinant tissue plasminogen activator, tPA) or streptokinase (SK) and to subcutaneous Heparin, beginning 12 h after the start of thrombolytic therapy or no heparin.
New England Journal of MedicineIncidence of Left-Ventricular Thrombosis after Acute Transmural Myocardial Infarction
583 Citations1981Richard Asinger, Frank L. Mikell +2 more
It is concluded that patients with severe apical-wall-motion abnormalities during acute transmural anterior myocardial infarction are at high risk for left-ventricular thrombosis and this high-risk group can be identified before the development of left-volatile thrombi.
CirculationImmediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study.
430 Citations1991Robert Roberts, William J. Rogers +8 more
In appropriate postinfarction patients, beta-blockers are safe when given early after thrombolytic therapy and are associated with decreased myocardial ischemia and reinfarction in the first week but offer no benefit over late administration in improving ventricular function or reducing mortality.
CirculationIntracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
320 Citations1991Joel M. Gore, M. A. Sloan +8 more
The small number of patients with any history of neurological disease, intermittent cerebral ischemic attacks, or stroke who were enrolled before the stricter eligibility criteria were imposed experienced an increased frequency of intracerebral hemorrhage compared with patients without such histories.
HeartEffect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
296 Citations1992D P de Bono, Maarten L. Simoons +8 more
Concomitant intravenous heparin improves coronary patency in patients with alteplase, and whether this can be translated into improved clinical benefit needs to be to be tested in a larger trial.
Annals of Internal MedicineLeft Ventricular Mural Thrombi Complicating Acute Myocardial Infarction
265 Citations1984David J. Weinreich, JAMES F. BURKE +1 more
Although anticoagulation treatment appeared to provide protection against embolic events, the prevalence of left ventricular thrombi on follow-up echocardiographic study was essentially the same whether or not this treatment was used.
The LancetLong-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study
223 Citations1990Aims Trial Study Group
Journal of the American College of CardiologyOptimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversies
210 Citations1990Cindy L. Grines, Anthony N. DeMaria
Thrombolytic therapy in the elderly may be two to three times that of the overall group of patients with myocardial infarction, and patients who present with hypotension or hypertension or who have undergone cardiopulmonary resuscitation may also benefit.
NeurologyMyocardial infarction and stroke
174 Citations1984Mark S. Komrad, C. Edward Coffey +4 more
Clinical and pathologic data suggested an embolic etiology for most strokes that complicate acute myocardial infarction, including peak creatine kinase and ventricular arrhythmia.
BMJStroke after acute myocardial infarction: relation to infarct size.
129 Citations1978Pauline Thompson, James S. Robinson
Two-thirds of the patients with acute myocardial infarction had negligible risk of stroke and did not need anticoagulant prophylaxis, suggesting that the peak enzyme values reflected infarct size.
Journal of the American College of CardiologyStroke and acute Myocardial Infarction in the Thrombolytic era: Clinical correlates and long-term prognosis
94 Citations1990Christopher M. O'Connor, M. Califf +10 more
Thirteen (1.8%) of 708 patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator in the Thrombolysis and Angioplasty in Myocardial Infarction I, II and III trials developed a stroke.
BMJCerebrovascular events after myocardial infarction: analysis of the GISSI trial. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).
75 Citations1991Aldo P. Maggioni, M.G. Franzosi +5 more
Although the incidence of cerebrovascular events complicating myocardial infarction was low, they increased morbidity and mortality and age and poor haemodynamic state were associated with an increased risk.
BMJBattle of the clotbusters.
24 Citations1991Martin O’Donnell
The data came from investigators in nearly 1 000 hospitals in Europe, North America, and Australasia who had treated over 46 000 patients suffering an acute myocardial infarction with one of three randomly assigned fibrinolytic agents : streptokinase, anistreplase, or tissue plasminogen activator (tPA).